Business Context and Reporting Period
This Form 8-K Current Report was filed by Tempest Therapeutics, Inc. on December 6, 2024, covering events occurring on December 3 and December 5, 2024. The filing primarily addresses corporate governance actions, specifically the approval of a reverse stock split and amendments to the company's Rights Agreement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate actions rather than financial performance metrics.
Material Changes and Corporate Actions
- Reverse Stock Split Approval: On December 3, 2024, stockholders approved a proposal to amend the Restated Certificate of Incorporation. This authorizes the Board to effect a reverse stock split of common stock at a ratio between 1-for-2 and 1-for-15, inclusive, at the Board's sole discretion.
- Voting Results: The proposal received 12,723,707 votes for, 9,810,591 votes against, and 415,687 abstentions.
- Rights Agreement Amendment: On December 5, 2024, the Company entered into Amendment No. 2 to its Rights Agreement with Computershare Trust Company, N.A. This amendment makes technical changes to the Board's administration and determination powers regarding the rights but leaves the agreement otherwise unmodified.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard disclosures related to the corporate actions. The primary contingency noted is the Board's future discretion to determine the specific ratio of the reverse stock split within the approved range.
Investor Verification Checklist
- Verify the specific reverse stock split ratio once determined by the Board of Directors.
- Review the full text of Amendment No. 2 to the Rights Agreement (Exhibit 4.1) to understand the technical changes to Board powers.
- Monitor subsequent filings for the effective date of the reverse stock split and any resulting changes to share count and trading price.
- Check the company's most recent 10-K or 10-Q for current financial health, as this 8-K does not contain financial data.